Satellos Bioscience (MSLE) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed PepGen (PEPG) over the past year, gaining 5.4% versus a loss of 51.1%. PepGen is the larger company by market cap ($166.0 million vs $161.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | PEPG |
|---|---|---|
| Share price | $7.63 | $2.40 |
| Market cap | $161.88M | $166.01M |
| 1-day change | +1.19% | +3.90% |
| YTD return | +29.76% | -63.13% |
| 1-year return | +5.44% | -51.12% |
| 5-year return | -48.93% | — |
| EPS (TTM) | $-1.94 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.40 | $7.80 |
| 52-week low | $5.30 | $1.31 |
| Distance from 52-week high | -43.04% | -69.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +244.04% | +324.58% |
| Average volume | 51.35K | 976.87K |
| Shares outstanding | 21.22M | 69.17M |
| Employees | 18 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed PEPG by 56.6 percentage points over the past year.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
MSLE vs PEPG FAQ
Which is bigger, Satellos Bioscience or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $166.01M compared with $161.88M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, MSLE or PEPG?
MSLE returned +5.44% over the past 12 months, compared with -51.12% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.